Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.41 |
| ▸ | CAD | P27708 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453134 | 0.89 | EPHX1 (0.43) | SMN1; SMN2MAPK1EPHX1ACHEALDH1A1 | |
| SCHEMBL7372859 | 0.89 | EPHX1 (0.43) | SMN1; SMN2MAPK1EPHX1ACHEALDH1A1 | |
| SCHEMBL7368743 | 0.85 | EPHX1 (0.43) | SMN1; SMN2EPHX1ACHEALDH1A1NPC1 | |
| SCHEMBL30202144 | 0.85 | EPHX1 (0.43) | SMN1; SMN2EPHX1ACHEALDH1A1NPC1 | |
| SCHEMBL10920272 | 0.85 | CPB2 (0.46) | SMN1; SMN2MAPK1L3MBTL1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL7656187 | 0.84 | EPHX1 (0.42) | SMN1; SMN2EPHX1ACHEALDH1A1NPC1 | |
| SCHEMBL8593917 | 0.81 | KMT2A (0.43) | SMN1; SMN2MAPK1EPHX1ACHEALDH1A1 | |
| SCHEMBL7006306 | 0.80 | KMT2A (0.49) | SMN1; SMN2MAPK1L3MBTL1POLBKMT2A | |
| SCHEMBL6168369 | 0.80 | KMT2A (0.49) | SMN1; SMN2MAPK1L3MBTL1POLBKMT2A | |
| SCHEMBL19084456 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPK1EPHX1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | SMN1; SMN2 4677/4885MAPK1 2486/4885EPHX1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.